179 related articles for article (PubMed ID: 22058419)
1. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
3. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
Akamatsu H; Inoue A; Mitsudomi T; Kobayashi K; Nakagawa K; Mori K; Nukiwa T; Nakanishi Y; Yamamoto N
Jpn J Clin Oncol; 2013 Jun; 43(6):664-8. PubMed ID: 23585689
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib in patients with advanced lung squamous cell carcinoma.
Chiang CL; Tsai CM; Chou TY; Chen YM; Lai SL; Shih JF; Chiu CH; Lee YC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):203-8. PubMed ID: 23053274
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Takahashi T; Yamamoto N; Nukiwa T; Mori K; Tsuboi M; Horai T; Masuda N; Eguchi K; Mitsudomi T; Yokota S; Segawa Y; Ichinose Y; Fukuoka M; Saijo N
Anticancer Res; 2010 Feb; 30(2):557-63. PubMed ID: 20332470
[TBL] [Abstract][Full Text] [Related]
7. Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
Takashima N; Kimura T; Watanabe N; Umemura T; Katsuno S; Arakawa K; Fukatsu M; Nakamura N; Nishiyama O; Kataoka K; Kondoh Y; Taniguchi H
Onkologie; 2012; 35(12):747-52. PubMed ID: 23207620
[TBL] [Abstract][Full Text] [Related]
8. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
Lee Y; Shim HS; Park MS; Kim JH; Ha SJ; Kim SH; Cho BC
Clin Cancer Res; 2012 Mar; 18(6):1760-8. PubMed ID: 22271877
[TBL] [Abstract][Full Text] [Related]
9. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S
Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546
[TBL] [Abstract][Full Text] [Related]
10. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
15. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment].
Romero-Ventosa EY; Mucientes-Molina A; Pedrido-Reino E; Lago-Rivero N; Constenla-Caramés L; Arias-Santos I
Farm Hosp; 2012; 36(2):68-76. PubMed ID: 21798783
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib in previously treated non-small-cell lung cancer.
Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Lind JS; Lagerwaard FJ; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
[TBL] [Abstract][Full Text] [Related]
20. Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Hirata K
Osaka City Med J; 2012 Jun; 58(1):25-34. PubMed ID: 23094511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]